Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 312 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo nasal spray Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

NCT05180500
View directory record Official record
Conditions
COVID-19, Pharmacokinetics, Safety
Interventions
Q-Griffithsin, Placebo
Drug
Lead sponsor
Sharon Hillier
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 3 Interventional

To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)

NCT00659841
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal, Hay Fever
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
6
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 2 Interventional Results available

Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals

NCT01963091
View directory record Official record
Conditions
Cocaine Dependence
Interventions
oxytocin, saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL)

NCT04739371
View directory record Official record
Conditions
Insulin
Interventions
Insulin, Regular, Human, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 3 Interventional

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

NCT00658918
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, Hay Fever
Interventions
Ciclesonide nasal, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
View directory record Official record
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 30, 2026, 7:02 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06397768
View directory record Official record
Conditions
RSV Immunization
Interventions
RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 12 Months
Enrollment
2,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 4 Interventional Results available

Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

NCT00449072
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Placebo, TAA-AQ, Nasacort® AQ, Claritin®
Other · Drug
Lead sponsor
Sanofi
Industry
Eligibility
3 Years to 9 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Adult Study Oxytocin - fMRI

NCT02566356
View directory record Official record
Conditions
Schizophrenia, Oxytocin, Social Cognition, Functional Magnetic Resonance Imaging (fMRI)
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 30, 2026, 7:02 PM EDT
Recruiting Phase 3 Interventional

ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

NCT06716021
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Placebo, Etripamil
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
West Hills, California • Littleton, Colorado • Haddon Heights, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 7:02 PM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients

NCT02147132
View directory record Official record
Conditions
Cigarette Smoking, Methadone Maintenance
Interventions
Nicotine Nasal Spray, Varenicline, Placebo Nasal Spray, Placebo Varenicline
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Neuropeptides and Social Behavior

NCT01680718
View directory record Official record
Conditions
Social Psychology
Interventions
Intranasal oxytocin, Intranasal vasopressin, Intranasal placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 4 Interventional

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05514041
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Varenicline solution, Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Drug
Lead sponsor
Stephenson Eye Associates
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

NCT02402465
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, Fluticasone propionate, Fluticasone/Azelastine nasal spray, Nasal Allergen Challenge
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Not applicable Interventional Results available

Oxytocin and CBSST for People With Schizophrenia

NCT01752712
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
CBSST + Oxytocin, CBSST + Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
San Diego, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Sep 30, 2026, 7:02 PM EDT
Terminated Phase 2 Interventional Results available

Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT02569437
View directory record Official record
Conditions
Polyp of Nasal Sinus
Interventions
Doxycycline, methylprednisolone, nasal saline spray, Flonase, sugar pill
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 1 Interventional

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

NCT06063330
View directory record Official record
Conditions
COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
Interventions
RQ-001, Placebo
Combination Product · Other
Lead sponsor
Red Queen Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

NCT01313962
View directory record Official record
Conditions
Influenza
Interventions
Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose, Flufirvitide-3, 0.4 mg single dose, Placebo
Drug · Other
Lead sponsor
Autoimmune Technologies, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2012 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

NCT00609674
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Baltimore, Maryland • Wheaton, Maryland • North Dartmouth, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

NCT00163501
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
41
States / cities
Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Results available

Oxytocin, Stress, Craving, Opioid Use Disorder

NCT04051619
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
intranasal oxytocin, 40 IU, twice a day for 7 days
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Sep 30, 2026, 7:02 PM EDT
Recruiting Phase 4 Interventional

Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

NCT02630121
View directory record Official record
Conditions
Sleep Apnea, Chronic Nasal Congestion
Interventions
Oxymetazoline Hydrochloride, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Sep 30, 2026, 7:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin and Affect Processing in Posttraumatic Stress Disorder

NCT02546570
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 30, 2026, 7:02 PM EDT